Equities research analysts at StockNews.com assumed coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV – Get Free Report) in a research report issued to clients and investors on Saturday. The brokerage set a “hold” rating on the biotechnology company’s stock.
Nabriva Therapeutics Stock Performance
Nabriva Therapeutics stock opened at $1.42 on Friday. The company has a current ratio of 0.85, a quick ratio of 0.52 and a debt-to-equity ratio of 0.12. The company has a market capitalization of $45.46 million, a price-to-earnings ratio of -0.07 and a beta of 1.53. Nabriva Therapeutics has a 1 year low of $1.22 and a 1 year high of $8.45.
Nabriva Therapeutics Company Profile
Further Reading
- Five stocks we like better than Nabriva Therapeutics
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- Where to Find Earnings Call Transcripts
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- What is the FTSE 100 index?
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.